GSK-A1
Cat. No.：YN252048
| 产品名称: | GSK-A1 |
| CAS No.: | 1416334-69-4 |
| Chemical Name: | 5-[2-amino-1-[4-(4-morpholinyl)phenyl]-1H-benzimidazol-6-yl]-N-(2-fluorophenyl)-2-methoxy-3-pyridinesulfonamide |
| Synonyms: | |
| 分子量: | 574.6271232 |
| 分子式: | C29H27FN6O4S |
| SMILES: | O=S(NC1=C(F)C=CC=C1)(C2=C(OC)N=CC(C3=CC4=C(N=C(N4C5=CC=C(N6CCOCC6)C=C5)N)C=C3)=C2)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | GSK-A1 是一种选择性 III 型磷脂酰肌醇 4-激酶 PI4KA (PI4KIIIα) 抑制剂，pIC50为 8.5-9.8。 GSK-A1 抑制 PtdIns(4,5)P2 再合成，IC50约为 3 nM。GSK-A1 有效降低 PtdIns(4)P 的水平，而对 PtdIns(4,5)P2 没影响。GSK-A1 有用于抗丙型肝炎病毒 (HCV) 研究的潜力。 |
| IC50和靶点: | [{name:"PI4KA:8.5-9.8 (pIC50)"},{name: "PI4KB:7.2-7.7 (pIC50)"},{name: "PI4K2A:<5 (pIC50)"},{name: "PI4K2B:<5 (pIC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Bojjireddy, N., Botyanszki, J., Hammond, G., et al.Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levelsJ. Biol. Chem.289(9),6120-6132(2014)
